Advertisement

Current Oncology Reports

, 17:50 | Cite as

Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics

  • Ysabella Z. A. Van SebilleEmail author
  • Romany Stansborough
  • Hannah R. Wardill
  • Emma Bateman
  • Rachel J. Gibson
  • Dorothy M. Keefe
Palliative Medicine (A Jatoi, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Palliative Medicine

Abstract

Chemotherapy-induced mucositis is a common condition caused by the breakdown of the mucosal barrier. Symptoms can include pain, vomiting and diarrhoea, which can often necessitate chemotherapy treatment breaks or dose reductions, thus compromising survival outcomes. Despite the significant impact of mucositis, there are currently limited clinically effective pharmacological therapies for the pathology. New emerging areas of research have been proposed to play key roles in the development of mucositis, providing rationale for potential new therapeutics for the prevention, treatment or management of chemotherapy-induced mucositis. This review aims to address these new areas of research and to comment on the therapeutics arising from them.

Keywords

Mucositis Toxicity Chemotherapy-induced gut toxicity Cancer side effects Zinc sulphate Palifermin R-spondin1 Benzydamine hydrochloride (HCl) Probiotics Antimicrobials Antioxidants Analgesics Coating agents Mucositis treatment 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Ysabella Z.A. Van Sebille declares that she has no conflict of interest.

Romany Stansborough declares that he has no conflict of interest.

Hannah R. Wardill declares that she has no conflict of interest.

Emma Bateman has received support through a grant from Entera Health.

Rachel J. Gibson has received support through a grant from Onyx Pharmaceuticals and has also received compensation from Onyx Pharmaceuticals for service as a consultant.

Dorothy M. Keefe has received research funding through grants from Helsinn, Pfizer and Entera Health and has also received compensation from Helsinn and Munipharma for serving on speakers’ bureaus.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51–63.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Sonis ST. Oral mucositis in cancer therapy. J Support Oncol. 2004;2(6 Suppl 3):3–8.PubMedGoogle Scholar
  3. 3.
    Sonis ST. A biological approach to mucositis. J Support Oncol. 2004;2(1):21-32. discussion 35-6.Google Scholar
  4. 4.••
    Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4(4):277–84. This paper describes in detail the currently accepted 5-phase pathophysiological model of mucositis.CrossRefPubMedGoogle Scholar
  5. 5.
    Cirillo M et al. Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol : Off J Eur Soc Med Oncol / ESMO. 2009;20(12):1929–35.CrossRefGoogle Scholar
  6. 6.
    Sonis S. et al. Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer. 2014.Google Scholar
  7. 7.
    Foote M. The importance of planned dose of chemotherapy on time: do we need to change our clinical practice? Oncologist. 1998;3(5):365–8.PubMedGoogle Scholar
  8. 8.
    Di Fiore F, Van Cutsem E. Acute and long-term gastrointestinal consequences of chemotherapy. Best Pract Res Clin Gastroenterol. 2009;23(1):113–24.CrossRefPubMedGoogle Scholar
  9. 9.
    Gibson RJ, Stringer AM. Chemotherapy-induced diarrhoea. Curr Opin Support Palliat Care. 2009;3(1):31–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Benson 3rd AB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(14):2918–26.CrossRefGoogle Scholar
  11. 11.
    Carlotto A et al. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. PharmacoEconomics. 2013;31(9):753–66.CrossRefPubMedGoogle Scholar
  12. 12.
    Elting LS et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98(7):1531–9.CrossRefPubMedGoogle Scholar
  13. 13.••
    Lalla RV et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453–61. This paper reviewed the available literature and produced evidence based guidelines for the management of patients with mucositis, impacting clinical practice.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Keefe DM. Gastrointestinal mucositis: a new biological model. Support Care Cancer. 2004;12(1):6–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Gibson RJ et al. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol. 2003;18(9):1095–100.CrossRefPubMedGoogle Scholar
  16. 16.•
    Al-Dasooqi N et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer. 2013;21(11):3233–41. This paper provided recent and emerging research directions, to drive new clinical research.CrossRefPubMedGoogle Scholar
  17. 17.
    Lalla RV, Ashbury FD. The MASCC/ISOO Mucositis Guidelines: dissemination and clinical impact. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer. 2013;21(11):3161–3.CrossRefGoogle Scholar
  18. 18.
    Davila M, Bresalier RS. Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol. 2008;5(12):682–96.CrossRefPubMedGoogle Scholar
  19. 19.
    Mehdipour M et al. A comparison between zinc sulfate and chlorhexidine gluconate mouthwashes in the prevention of chemotherapy-induced oral mucositis. Daru. 2011;19(1):71–3.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Arbabi-kalati F et al. Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: a double-blind randomized clinical trial. Arch Iran Med. 2012;15(7):413–7.PubMedGoogle Scholar
  21. 21.
    Mansouri A et al. The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study. Hematol Oncol. 2012;30(1):22–6.CrossRefPubMedGoogle Scholar
  22. 22.•
    Raber-Durlacher JE et al. Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(1):343–55. This paper provided evidence based guidelines for the use of growth factors, including palifermin, in patients with mucositis.CrossRefPubMedGoogle Scholar
  23. 23.
    Goldberg JD et al. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant. 2013;48(1):99–104.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Blijlevens N et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient’s burden. Bone Marrow Transplant. 2013;48(7):966–71.CrossRefPubMedGoogle Scholar
  25. 25.
    Vadhan-Raj S et al. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med. 2010;153(6):358–67.CrossRefPubMedGoogle Scholar
  26. 26.
    Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3(7):521–33.CrossRefPubMedGoogle Scholar
  27. 27.
    Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology. 2001;120(3):622–35.CrossRefPubMedGoogle Scholar
  28. 28.
    Holmberg J et al. EphB receptors coordinate migration and proliferation in the intestinal stem cell niche. Cell. 2006;125(6):1151–63.CrossRefPubMedGoogle Scholar
  29. 29.
    Bhanja P et al. Protective role of R-spondin1, an intestinal stem cell growth factor, against radiation-induced gastrointestinal syndrome in mice. PLoS One. 2009;4(11), e8014.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Zhao J et al. R-Spondin1 protects mice from chemotherapy or radiation-induced oral mucositis through the canonical Wnt/beta-catenin pathway. Proc Natl Acad Sci U S A. 2009;106(7):2331–6.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Abraham C, Cho JH. Inducing intestinal growth. N Engl J Med. 2005;353(21):2297–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Kim KA et al. Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science. 2005;309(5738):1256–9.CrossRefPubMedGoogle Scholar
  33. 33.•
    Zhou WJ, Zhou WJ, et al. Induction of intestinal stem cells by R-spondin 1 and Slit2 augments chemoradioprotection. Nature. 2013;501(7465):107–11. This paper provided evidence of the protective role of R-spondin1 in chemoradiation-induced mucositis.CrossRefPubMedGoogle Scholar
  34. 34.
    Kazemian A et al. Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care (Engl). 2009;18(2):174–8.CrossRefGoogle Scholar
  35. 35.
    Logan RM et al. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol. 2008;62(1):33–41.CrossRefPubMedGoogle Scholar
  36. 36.
    Keefe DM et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109(5):820–31.CrossRefPubMedGoogle Scholar
  37. 37.•
    Sheibani KM et al. Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: a double-blind placebo-controlled randomized clinical trial. Asia Pac J Clin Oncol. 2015;11(1):22–7. This paper provided evidence on the efficacy of benzydamine HCl in the prevention of radiation induced oral mucositis.CrossRefPubMedGoogle Scholar
  38. 38.
    Epstein JB et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer. 2001;92(4):875–85.CrossRefPubMedGoogle Scholar
  39. 39.
    Osterlund P et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007;97(8):1028–34.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Abd El-Atti S et al. Use of probiotics in the management of chemotherapy-induced diarrhea: a case study. JPEN J Parenter Enteral Nutr. 2009;33(5):569–70.CrossRefPubMedGoogle Scholar
  41. 41.
    Mego M et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement Ther Med. 2015;23(3):356–62.CrossRefPubMedGoogle Scholar
  42. 42.
    Ciorba MA, Stenson WF. Probiotic therapy in radiation-induced intestinal injury and repair. Ann N Y Acad Sci. 2009;1165:190–4.PubMedCentralCrossRefPubMedGoogle Scholar
  43. 43.
    Ciorba MA. A gastroenterologist’s guide to probiotics. Clin Gastroenterol Hepatol. 2012;10(9):960–8.PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Stringer AM et al. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol. 2009;90(5):489–99.PubMedCentralCrossRefPubMedGoogle Scholar
  45. 45.
    Stringer AM et al. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood). 2007;232(1):96–106.Google Scholar
  46. 46.
    Bowen JM et al. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther. 2007;6(9):1449–54.CrossRefPubMedGoogle Scholar
  47. 47.
    Prisciandaro LD et al. Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats. Cancer Biol Ther. 2011;11(7):671–7.CrossRefPubMedGoogle Scholar
  48. 48.
    Ciorba MA et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut. 2012;61(6):829–38.PubMedCentralCrossRefPubMedGoogle Scholar
  49. 49.
    Wardill HR, Bowen JM, Gibson RJ. New pharmacotherapy options for chemotherapy-induced alimentary mucositis. Expert Opin Biol Ther. 2014;14(3):347–54.CrossRefPubMedGoogle Scholar
  50. 50.
    Bossi P et al. Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. Support Care Cancer. 2014;22(7):1889–96.PubMedGoogle Scholar
  51. 51.
    Sorensen JB et al. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer. 2008;112(7):1600–6.CrossRefPubMedGoogle Scholar
  52. 52.
    Orvain C et al. Miconazole mucoadhesive buccal tablet in high-dose therapy with autologous stem cell transplantation (HDT/ASCT)-induced mucositis. Support Care Cancer. 2015;23(2):359–64.CrossRefPubMedGoogle Scholar
  53. 53.
    Lin JX et al. A comparison of dioctahedral smectite and iodine glycerin cream with topical mouth rinse in treatment of chemotherapy induced oral mucositis: a pilot study. Eur J Oncol Nurs. 2015;19(2):136–41.CrossRefPubMedGoogle Scholar
  54. 54.
    Rao NG et al. Effect of prophylactic fluconazole on oral mucositis and candidiasis during radiation therapy for head-and-neck cancer. Pract Radiat Oncol. 2013;3(3):229–33.CrossRefPubMedGoogle Scholar
  55. 55.
    Bensadoun RJ et al. Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer. 2008;112(1):204–11.CrossRefPubMedGoogle Scholar
  56. 56.
    Moslehi A et al. N-acetyl cysteine for prevention of oral mucositis in hematopoietic SCT: a double-blind, randomized, placebo-controlled trial. Bone Marrow Transplant. 2014;49(6):818–23.CrossRefPubMedGoogle Scholar
  57. 57.
    Tsujimoto T et al. L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. Oncol Rep. 2015;33(1):33–9.PubMedCentralPubMedGoogle Scholar
  58. 58.
    Chattopadhyay S et al. Role of oral glutamine in alleviation and prevention of radiation-induced oral mucositis: a prospective randomized study. South Asian J Cancer. 2014;3(1):8–12.PubMedCentralCrossRefPubMedGoogle Scholar
  59. 59.
    Gibson RJ et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer. 2013;21(1):313–26.CrossRefPubMedGoogle Scholar
  60. 60.
    Blijlevens NM et al. A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients. Support Care Cancer. 2005;13(10):790–6.CrossRefPubMedGoogle Scholar
  61. 61.
    Sornsuvit C et al. Pilot Study: effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients. J Int Med Res. 2008;36(6):1383–91.CrossRefPubMedGoogle Scholar
  62. 62.
    Li Y et al. Oral glutamine ameliorates chemotherapy-induced changes of intestinal permeability and does not interfere with the antitumor effect of chemotherapy in patients with breast cancer: a prospective randomized trial. Tumori. 2006;92(5):396–401.PubMedGoogle Scholar
  63. 63.
    Leenstra JL et al. Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]). J Clin Oncol. 2014;32(15):1571–7.PubMedCentralCrossRefPubMedGoogle Scholar
  64. 64.
    Epstein JB et al. Doxepin rinse for management of mucositis pain in patients with cancer: one week follow-up of topical therapy. Spec Care Dentist. 2008;28(2):73–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Guo SP et al. Transdermal fentanyl for pain due to chemoradiotherapy-induced oral mucositis in nasopharyngeal cancer patients: evaluating efficacy, safety, and improvement in quality of life. Drug Des Devel Ther. 2014;8:497–503.PubMedCentralPubMedGoogle Scholar
  66. 66.
    Vokurka S et al. The effect of polyvinylpyrrolidone-sodium hyaluronate gel (Gelclair) on oral microbial colonization and pain control compared with other rinsing solutions in patients with oral mucositis after allogeneic stem cells transplantation. Med Sci Monit. 2011;17(10):CR572–6.PubMedCentralCrossRefPubMedGoogle Scholar
  67. 67.
    Velez I et al. MuGard, an oral mucoadhesive hydrogel, reduces the signs and symptoms of oral mucositis in patients with lichen planus: a double-blind, randomized, placebo-controlled pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118(6):657–64e2.CrossRefPubMedGoogle Scholar
  68. 68.
    Hadjieva T et al. Treatment of oral mucositis pain following radiation therapy for head-and-neck cancer using a bioadhesive barrier-forming lipid solution. Support Care Cancer. 2014;22(6):1557–62.PubMedCentralCrossRefPubMedGoogle Scholar
  69. 69.
    Yarom N et al. Systematic review of natural agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(11):3209–21.CrossRefPubMedGoogle Scholar
  70. 70.
    Carvalho PA et al. Evaluation of low-level laser therapy in the prevention and treatment of radiation-induced mucositis: a double-blind randomized study in head and neck cancer patients. Oral Oncol. 2011;47(12):1176–81.CrossRefPubMedGoogle Scholar
  71. 71.
    Silva GB et al. The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial. Photomed Laser Surg. 2011;29(1):27–31.CrossRefPubMedGoogle Scholar
  72. 72.
    Schubert MM et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer. 2007;15(10):1145–54.CrossRefPubMedGoogle Scholar
  73. 73.
    Cowen D et al. Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Radiat Oncol Biol Phys. 1997;38(4):697–703.CrossRefPubMedGoogle Scholar
  74. 74.
    Jaguar GC et al. Low-energy laser therapy for prevention of oral mucositis in hematopoietic stem cell transplantation. Oral Dis. 2007;13(6):538–43.CrossRefPubMedGoogle Scholar
  75. 75.
    Whelan HT et al. NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patients. J Clin Laser Med Surg. 2002;20(6):319–24.CrossRefPubMedGoogle Scholar
  76. 76.
    Barasch A et al. Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer. 1995;76(12):2550–6.CrossRefPubMedGoogle Scholar
  77. 77.
    Silva GB et al. Effect of low-level laser therapy on inflammatory mediator release during chemotherapy-induced oral mucositis: a randomized preliminary study. Lasers Med Sci. 2015;30(1):117–26.CrossRefPubMedGoogle Scholar
  78. 78.
    Antunes HS et al. Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial. Blood. 2007;109(5):2250–5.CrossRefPubMedGoogle Scholar
  79. 79.
    Bensadoun RJ, Nair RG. Low-level laser therapy in the prevention and treatment of cancer therapy-induced mucositis: 2012 state of the art based on literature review and meta-analysis. Curr Opin Oncol. 2012;24(4):363–70.CrossRefPubMedGoogle Scholar
  80. 80.
    Migliorati C et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(1):333–41.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Ysabella Z. A. Van Sebille
    • 1
    Email author
  • Romany Stansborough
    • 1
  • Hannah R. Wardill
    • 1
  • Emma Bateman
    • 1
  • Rachel J. Gibson
    • 1
  • Dorothy M. Keefe
    • 1
  1. 1.School of MedicineUniversity of AdelaideAdelaideAustralia

Personalised recommendations